#Neupogen

[phonemantra-blog]

Neulasta: Benefits, Side Effects, and Uses Neulasta is a medication that plays a crucial role in cancer treatment, particularly for individuals undergoing chemotherapy. It's essential for patients and caregivers to have a comprehensive understanding of Neulasta's significance in healthcare. In this article, we will delve into what Neulasta is, how it works, its indications, benefits, potential side effects, and much more. What Is Neulasta? Neulasta belongs to a class of drugs known as colony-stimulating factors. Its primary function is to stimulate the production of white blood cells, specifically neutrophils, which are vital for the body's immune system. Neulasta is often prescribed to cancer patients who are at risk of experiencing a significant drop in white blood cell counts due to chemotherapy. By boosting white blood cell production, Neulasta helps reduce the risk of infections and related complications during cancer treatment. [caption id="attachment_50673" align="aligncenter" width="598"] neulasta[/caption] Indications and Uses Chemotherapy-Induced Neutropenia: Neulasta is frequently prescribed to cancer patients undergoing chemotherapy. Chemotherapy can suppress the bone marrow's ability to produce white blood cells, leaving patients vulnerable to infections. Neulasta helps address this issue by stimulating the production of neutrophils, a type of white blood cell responsible for fighting off infections. Bone Marrow Disorders: In some cases, Neulasta may be used to treat bone marrow disorders that lead to low white blood cell counts. These conditions can occur independently of cancer and require specific medical management. Stem Cell Transplantation: Neulasta may also be part of the treatment plan for patients undergoing stem cell transplantation, as it aids in the recovery of white blood cell counts after the procedure. How Does Neulasta Work? Neulasta's mechanism of action revolves around stimulating the bone marrow to produce more neutrophils, a specific type of white blood cell essential for the body's immune response. Here's a simplified breakdown of how Neulasta works: Chemotherapy and Neutropenia: During chemotherapy, the bone marrow's ability to generate white blood cells, including neutrophils, can be severely compromised. Neutropenia, or a low neutrophil count, is a common side effect of chemotherapy. This condition weakens the patient's immune system, making them susceptible to infections. Stimulating Neutrophil Production: Neulasta contains a medication called pegfilgrastim, which is a synthetic version of a natural protein called granulocyte-colony stimulating factor (G-CSF). Pegfilgrastim works by binding to receptors on the surface of certain cells in the bone marrow, signaling them to increase the production and release of neutrophils into the bloodstream. Protection Against Infections: By boosting the production of neutrophils, Neulasta helps restore the patient's white blood cell count to more normal levels. This, in turn, enhances their ability to combat infections effectively. For cancer patients undergoing chemotherapy, Neulasta can be a critical component of their treatment plan, reducing the risk of serious infections and treatment interruptions. Benefits of Neulasta The use of Neulasta in cancer treatment offers several significant benefits: Reduced Infection Risk: Chemotherapy-induced neutropenia can leave patients highly vulnerable to infections. Neulasta mitigates this risk by elevating neutrophil counts, bolstering the body's defense against pathogens. Enhanced Treatment Continuation: Maintaining a proper white blood cell count allows patients to adhere to their chemotherapy schedule. Uninterrupted treatment is vital for the effectiveness of cancer therapy. Improved Quality of Life: With reduced infection-related complications, patients experience a better quality of life during their cancer treatment journey. They are less likely to face hospitalizations or treatment delays due to infections. Minimal Side Effects: Neulasta is generally well-tolerated, with few side effects. Common side effects, if any, are typically mild and temporary. Potential Side Effects While Neulasta is generally well-tolerated, it's crucial to be aware of potential side effects. These side effects can vary in severity, and not everyone will experience them. Common side effects may include: Bone Pain: Some patients may experience bone pain, typically in the lower back or pelvis. This pain is usually mild to moderate and can be managed with over-the-counter pain relievers as recommended by a healthcare provider. Muscle Aches: Muscle aches are another common side effect. Like bone pain, they are generally manageable and temporary. Headache: Headaches may occur but are usually mild and transient. Redness or Swelling at the Injection Site: If Neulasta is administered as an injection, redness or swelling at the injection site can occur. This is usually mild and short-lived. Nausea: Some patients may experience nausea, although this is less common. Neulasta Administration Neulasta is typically administered as a subcutaneous injection. The injection is usually given approximately 24 hours after chemotherapy to allow for optimal neutrophil production. The specific dosing and timing will be determined by your healthcare provider based on your treatment regimen. Safety Considerations When using Neulasta, safety considerations include: Allergic Reactions: While rare, allergic reactions to Neulasta can occur. Symptoms may include difficulty breathing, rash, itching, swelling, or dizziness. Seek immediate medical attention if you experience any signs of an allergic reaction. Monitoring: Your healthcare provider will monitor your white blood cell counts regularly to ensure that Neulasta is effectively increasing neutrophil production. Individualized Treatment: Neulasta dosing and administration are personalized to each patient's needs. It's crucial to strictly adhere to the prescribed treatment plan. Consultation: Always consult your healthcare provider if you have questions or concerns about Neulasta or experience any unusual symptoms. Patient Experiences Hearing about the experiences of others who have used Neulasta can provide valuable insights into its real-world impact. Here are a couple of patient stories: Sarah's Story Sarah, a breast cancer survivor, shared her experience with Neulasta. "During my chemotherapy, my immune system was weakened, and I was constantly worried about infections. Neulasta made a significant difference. I experienced some bone pain, but it was manageable with pain relievers. Thanks to Neulasta, I completed my treatment without any major setbacks." Mark's Journey Mark, a lymphoma patient, also benefited from Neulasta. "I was concerned about the risk of infections during my chemotherapy. My doctor recommended Neulasta, and it allowed me to stay on track with my treatment. The bone pain was there, but it was worth it to keep my white blood cell count up. I felt more confident throughout my treatment journey." These stories highlight how Neulasta can positively impact the lives of cancer patients, helping them maintain their treatment schedules and improve their overall well-being. Neulasta vs. Other Medications In some cases, Neulasta may not be the only option for managing neutropenia during cancer treatment. It's essential to consider how Neulasta compares to other medications in the same category. Here are some points of comparison: Neulasta vs. Neupogen Neulasta and Neupogen are both medications used to stimulate white blood cell production, but they differ in how they are administered. Neulasta is administered as a single, long-acting injection, usually 24 hours after chemotherapy. Neupogen, on the other hand, is given as a daily injection. While Neupogen may require more frequent dosing, it can be a suitable alternative for some patients. Neulasta vs. Zarxio Zarxio is another medication similar to Neulasta. It is a biosimilar to Neulasta, meaning it has a highly similar structure and function. Biosimilars like Zarxio can offer a more cost-effective option while providing similar benefits. Frequently Asked Questions (FAQs) 1. Is Neulasta the only medication for boosting white blood cell counts during chemotherapy? Neulasta is one of the medications used for this purpose, but there are alternatives like Neupogen and Zarxio. The choice depends on individual patient needs and preferences. 2. Are the side effects of Neulasta severe? Common side effects like bone pain and muscle aches are generally mild and manageable. However, it's essential to discuss any side effects with your healthcare provider. 3. Can Neulasta be self-administered at home? In some cases, patients may be taught to self-administer Neulasta injections at home. This allows for more flexibility in treatment. 4. How long does it take for Neulasta to increase white blood cell counts? Neulasta typically starts working within a day after administration. It boosts white blood cell counts, reducing the risk of infections. 5. Are there any dietary restrictions while using Neulasta? Neulasta doesn't usually require specific dietary restrictions. However, maintaining a balanced diet and staying hydrated is essential for overall health during cancer treatment. 6. Can Neulasta be used in pediatric cancer patients? Neulasta is generally indicated for adults. Pediatric patients may have different treatment options, and the decision is made based on their specific medical needs. 7. What should I do if I miss a Neulasta injection? If you miss a scheduled Neulasta injection, contact your healthcare provider for guidance. It's crucial to stay on track with your treatment plan. 8. How is Neulasta different from chemotherapy? Neulasta is not chemotherapy; it is a medication used in conjunction with chemotherapy. While chemotherapy directly targets cancer cells, Neulasta focuses on boosting the body's immune response to reduce infection risk. 9. Can I continue my regular activities while using Neulasta? Yes, you can generally continue with your daily activities while using Neulasta. However, it's essential to follow your healthcare provider's recommendations regarding rest and physical activity. 10. What should I do if I experience an allergic reaction to Neulasta? If you suspect an allergic reaction (e.g., difficulty breathing, rash, swelling), seek immediate medical attention. Allergic reactions to Neulasta are rare but should be addressed promptly. Conclusion: Neulasta plays a vital role in supporting cancer patients undergoing chemotherapy. By boosting white blood cell counts, it helps reduce the risk of infections and allows patients to stay on track with their treatment regimens. While it may have some side effects, the benefits of Neulasta in improving patients' quality of life during cancer treatment are significant. If you or a loved one is considering Neulasta as part of your treatment plan, consult with your healthcare provider to determine the most suitable approach tailored to your needs.

[yourcancerguru]

Treating Bone Pain From Neulasta and Neupogen

Bone pain is a common side effect of Neulasta (pegfilgrastim) and Neupogen (filgrastim), which are medications given after chemotherapy to increase one's white blood cell count. While these medications are effective in reducing the risk of infection, they can also cause bone pain since they stimulate the bone marrow to produce more white blood cells. Pain can vary in intensity, from mild to severe. Commonly affected areas include the lower back, hips, thighs, and sternum. Here is a comprehensive approach to help manage and alleviate bone pain. 

1. Dietary Adjustments

Anti-inflammatory Foods: Incorporate foods rich in omega-3 fatty acids (like salmon, flaxseeds, and walnuts), antioxidants (such as berries, leafy greens, and nuts), and spices like turmeric and ginger, which have natural anti-inflammatory properties.

Hydration: Staying well-hydrated helps maintain overall health and can alleviate some discomfort. Aim for at least 8-10 glasses of water a day.

Magnesium-Rich Foods: Magnesium can help relax muscles and ease pain. Include foods such as spinach, almonds, avocados, and bananas in your diet.

2. Natural Supplements

Omega-3 Fatty Acids: Omega-3 supplements can reduce inflammation and may help alleviate bone pain. Fish oil and kelp (which is vegan) are common sources. The recommended daily dose is 1,000 mg per day.  

Vitamin D and Calcium: These nutrients are vital for bone health. Ensure adequate intake of both to support bone strength and potentially reduce pain. Most adults need 5,000 IU of vitamin D per day to maintain ideal levels, but ask your doctor based on your current vitamin D level.  The recommended daily intake of calcium is 1,000 mg per day. 

Magnesium: This mineral can help relax muscles and ease pain. Consider a magnesium supplement.  The recommended dose is usually 300-400 mg per day.

3.  Herbal Remedies

Turmeric and Ginger: Both herbs have potent anti-inflammatory effects. Turmeric can be taken as a supplement or added to meals, while ginger can be consumed as tea or in food.

Boswellia: Boswellia (frankincense) is an herbal extract that has anti-inflammatory properties and can be an effective natural pain reliever.  The recommended dose is 500 mg, twice a day.

Willow Bark: Known as nature's aspirin, willow bark can help reduce inflammation and pain. The daily dose should be equal to 240 mg of salicin (active ingredient) per day.  

4.  Conventional Treatment

Tylenol: Ask your doctor before taking as tylenol should not be taken by those with liver disease. The recommended dose is 500 - 1,000 mg every 6 hours, as needed.

 Loratadine: Loratadine (Claritin) is an antihistamine that can reduce bone pain due to reducing the amount of histamines in the body and reducing inflammation. The recommended dose for adults is 10 mg per day.  Make sure to ask your doctor before taking this, especially if you have kidney or liver disease. 

5. Physical Therapies

Acupuncture: Acupuncture has been proven to decrease pain by turning off pain signals in the brain, releasing endorphins in the bloodstream, reducing inflammation, and circulating Qi and Blood.

Massage Therapy: Professional massage can improve circulation, reduce muscle tension, and provide pain relief.

Gentle Exercise: Regular, low-impact exercises like walking, swimming, or yoga can help maintain mobility and reduce pain. Exercise also releases endorphins, which are natural painkillers.

6. Lifestyle Adjustments

Adequate Rest: Ensure you are getting enough sleep as it is essential for the body to heal and recover.

Stress Management: Chronic stress can exacerbate pain. Incorporate stress-reducing activities into your routine, such as hobbies, spending time in nature, or practicing meditation, and/or relaxation techniques.

Conclusion

Managing bone pain from Neulasta and Neupogen involves an integrative approach. Combining dietary adjustments, natural supplements, herbal remedies, conventional treatment, physical therapies, and lifestyle adjustments can offer significant relief. Always consult with healthcare providers before starting any new treatment to ensure it’s safe and appropriate for your specific condition. 

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[meditation-practices]

A Pot To Pee In

A Pot To Pee In

I started my second cycle of chemotherapy this morning with two hours of hydration, anti-nausea drugs, and gemcitabine. In order to qualify to receive the gemcitabine, I had to produce more urine. The nurses have been collecting my urine all day to insure I was fully hydrated. So don’t say to me, “You don’t have a pot to pee in!” Now rather cisplatin is dripping and I’ve been thinking about the…

[siglerprescriptiondrugcards]

Filgrastim

Common Brand Names: Neupogen

Therapeutic Class: A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes.

Common Injectable Dosage Forms:

Injection: 300 mcg/mL (1 mL, 1.6 mL), 600 mcg/mL (0.5 mL, 0.8 mL)

Dosage Ranges:

The recommended initial dose is 5 mcg/kg/day for up to 2 weeks or until the absolute neutrophil count reaches 10,000/mm3 for patients that are in post-antineoplastic therapy states.

In bone marrow transplantation, dosage is 10 mcg/kg/day and adjusted accordingly.

Administration and Stability: The commercially available solution (300 mcg/mL) may be given by direct rapid SQ injection. When given by IV infusion, the desired dose should be diluted with 50-100 mL of D5W to a concentration not less than 5 mcg/mL and may be given over 15-60 minutes or infused continuously over 24 hours. For continuous SQ infusion, the dose is diluted with 10-50 mL of D5W and administered at a rate not exceeding 10 mL/24 hours. When diluted to less than 15 mcg/mL, the solution should have 2 mcg/mL of albumin added to lessen the likelihood of adsorption. pH 4

Pharmacology/Pharmacokinetics: Filgrastim exerts its hematopoietic effects primarily by binding to neutrophil progenitor target cells that acts to stimulate proliferation of neutrophils within the bone marrow and possibly other sites. Following subcutaneous bolus administration, peak serum levels are observed in 2-6 hours. It is rapidly distributed with highest concentrations in the bone marrow, adrenal glands, kidney, and liver. The elimination half-life is 1.5-7 hours.

Drug and Lab Interactions: Filgrastim should not be administered within 24 hours before or after a dose of myelosuppressive antineoplastic agent. Because of transient decreases in platelet counts following filgrastim doses, caution should be used with patients on other platelet depressing agents. Lithium could theoretically potentiate the effects of filgrastim, but this has not been clinically established.

Contraindications/Precautions: Contraindicated in patients with known sensitivity to any proteins derived from E. coli. CBC and platelet counts should be performed prior to initiation and at least twice weekly during therapy to avoid the possibility of excessive leukocytosis or thrombocytopenia. Caution should be exercised in patients with suspected myeloid malignancies as tumor growth could be stimulated by filgrastim therapy. Pregnancy Category C.

Monitoring Parameters: CBC with diff., monitor for neutropenia.

Adverse Effects: The most common adverse effect is bone pain; other less common reactions include fever, elevations in serum uric acid, local cutaneous reactions, and occasionally, splenomegaly.

Common Clinical Applications: Effective in decreasing the incidence of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive therapy, and in reducing duration of neutropenia when undergoing myeloablative chemotherapy.

[maflufla]

Please help me finish my cat’s cancer treatment

Hi, I have never done this but I really don’t know what else to do. My name is Mafe and this is my cat, Ramona: 

At the beginning of the year I found a growth on her back, which turned out to be a tumor. I took her to the vet, where they removed the tumor

it turned out to be a vaccine induced fibrosarcoma, which is a fairly rare cancer that has high probabilty of relapsing constantly throughout her life. In order to reduce the chances of relapsing, a very agressive chemotherapy following the removal of the tumor is recommended. She has now received 4 sessions of chemotherapy, and still has three to go. She additionally has to receive 3 doses of Neupogen, to stimulate the production of white cells, since her white cell count is very low due to the chemotherapy. 

The remaining treatments cost 870,000.00 COP, which are about 236 USD. I have no money left and would really like to finish her treatment, to give her the best chances to survive it. Any donation would be really really helpful, because dollars multiplie here. My paypal is: 

https://paypal.me/mfgaviria?locale.x=es_XC  

Any reblog also helps a lot.

Thank you to anybody who reads this. 

[dryeyesyndrometherapeuticsma]

dry eye disease market size

The global organic drugs industry could be largely classified as: vaccines, healing protein, and mAb. The part of healing proteins could be split into: Avonex, Enbrel, Neulasta, Lantus, NovoLog, Humalog, Aranesp, Rebif, Levemir, Epogen, Victoza, Neupogen, Betaseron, and Eylea. Likewise, the mAb part could be divided into: Remicade, Humira, Rituxan, Herceptin, Avastin, and Lucentis. And, the part for vaccines could be sub-segmented as: Cervarix, Gardasil, Varivax, Prevnar 13, and Fluzone.The industry for organic drugs could be classified and studied on the cornerstone of geographical regions. Thus, the marketplace could be split into: North America, Europe, Asia Pacific, and Remaining portion of the World. By industry share, North America emerges as the dominant region. It is dry eye market size in india

In North America, the global industry is fuelled by the rising utilization of such drugs for treating chronic diseases as well as diabetes and cancer. A case in point will be the National College of Rheumatology's advice of infection altering antirheumatic drugs as well as biologic brokers in treating rheumatoid arthritis in 2012. The National College of Rheumatology is definitely an business dedicated to developing treatment plans for rheumatic conditions via education and researchAs new breakthroughs are made in the biomedicine field, growth is also anticipated in the organic drugs market. According to U.S.-based industry study firm Persistence Market Research, this industry can record a 10% CAGR from 2014 through 2020, and will undoubtedly be dry eye disease market size

In different areas such as Europe, the growth of the marketplace could be ascribed to a spike in the geriatric population. A written report by the United Nations claims that at the time of 2000, seniors comprised 23.2% of the total citizenry of Germany. This percentage can properly scale to 33.2% by 2025. Glaucoma and macular degeneration are age-related problems that create possibilities for the development of treatment plans such as drugs.A healthy percentage of the total investments by organic medicine designers has become being noticed in Asian countries. The reduced production costs that win here, combined with rising move of pharmaceutical know-how from the West to the East, can support the growth of the marketplace here. A recent case would be that of Swiss biotech organization, Lonza, which invested a reported USD 350 million in two Asian places - Singapore and India - to improve organic drug-related activities.  Dry Eye Syndrome Therapeutics Market size

[enzaime-blog]

Always Have Hope

New Story has been published on https://enzaime.com/always-have-hope/

Always Have Hope

A few months ago, I thought it was the beginning of the end; I thought I was dying. My cancer had been spreading like wild fire through my weak and tired body for eight months. My oncologist told me my treatment options were becoming limited. How could I not think I was dying?

I never give up hope and I believe in miracles. My family and friends give me much love and support, which helps get through the rough times and celebrate the good times. I was so happy this week to share some good news, finally. I am not dying, at least for the time being.

Last Tuesday I received scans. Thursday, I met with Dr. M to discuss the scans and treatment. Dr. M came in the room with a big smile on her face. She said hello, shook Mark and my hands, and sat down. The first sentence out of her mouth was, “I am thilled with your scans.” All tumors, lesions, and lymph nodes have shrunk. My tumor markers have come down 90%…. WOW! Dr. M and I hugged with big smiles on our faces. Mark had a big smile on his face too.

I love receiving good news about my condition, but I always remain cautious. Some treatments last for a long time, some do not. I have experienced both sides of treatments. However, I am thrilled, and rejoicing at this wonderful news.

Eribulin, my chemotherapy, will be given every other week instead of two weeks on and one week off. My white and blood red blood counts go way down after receiving Eribulin and take more than a week to come up in order to receive chemo. This is because my bone marrow is tired from receiving so much chemotherapy. I will also be taking neupogen injections to help keep the white counts from getting too low.

As you might know, I try to look for the silver lining in everything. Right now the silver lining is weight loss! Between my thyroid, and cancer treatments starting in 2010, my weight fluctuated quite a bit. In March of this year, I lost my appetite. This continued until June before starting the Eribulin. I am happy to say my appetite has returned! I am content with my weight now. I needed a new wardrobe, and Michaela and I had a lot of fun shopping for new clothes… And we still are!

Thanks for reading my blog, and supporting me through the ups and the downs. This photo was taken a couple of weeks ago by the talented Paul Vicario. He, and the talented Dee Lewis have captured the “real me” through their beautiful photos.

[mindfullymedical]

Swabbed my cheek to join the marrow registry today, It’s rare to be a match, but if I am- residency should give me a day off right?

I just hope I match for marrow rather than stem cells... I’ve had patients feel pretty crummy on Neupogen and I don't want to have to work feeling achy ann flu-like before the donation. 

Also I encourage every healthy person to register!

[gracievanbrunt]

It is so weird how my two worlds of music and my rare disease collide sometimes because I am sitting in the hospital right now while I am listening to my new single "Siren" which is my first release on a label!!

I'll guess I'll talk about what's going on with my SDS first. Over the past few weeks my blood counts have been gradually decreasing, something that was concerning my doctor and something that was very unexpected. Dr. Antin explained to me that in order to get my counts up and my transplant recovery progress back on track I would need to get more stem cells from Bradlee.

So we had Bradlee fly out for the week to receive his Neupogen shots (they allow your stem cells to rise to the surface of your blood for easier extraction) and yesterday he was hooked up to this crazy machine for a few hours while they collected and cleaned his blood! Luckily, no surgery this time for bone-marrow.

Today I am sitting in my little infusion room receiving his stem cells. To be honest, when I first got the news I was pretty frustrated that my body wasn't doing what I wanted it to, especially because there's nothing you yourself can do to improve your blood. When you get a cold, you can take care of yourself with cold medication and Vitamin C, when you want to lose weight you can start eating healthy and exercising...when you want your blood counts to do better there's literally nothing you can do except get infusions from a doctor. It's frustrating to not always be in control of your body and to feel like it is failing you.

But I have confidence that today's stem cells are going to do great and I want to thank my brother, Bradlee, for making the effort to come all the way from Detroit for the week and give me more of his blood!!

NOWWW onto the fun news!

In April I was contacted by a DJ named Kiba to topline one of their tracks. This was right around the time when my boyfriend, Louie, and I were gearing up to move from LA to Boston for the transplant. I got the track from Kiba and  with my wonderful songwriting partner, Liza , I guess I just started writing about how I was feeling with everything going on. I sent them a rough draft of it and they instantly loved it! I finished the topline for them and they began shopping it around to different labels.

We finally landed upon Simplify Records for the release and now it is here today!!!!!

This song came from a very real place and it means a lot to me! I hope you can feel that when you listen to it =)

Please go stream!!

Thank you all for your continuous support as always!

With much love and gratittude,

Gracie

[deannaanderson]

Biosimilar Litigation Trends and Best practices we have learnt in 2019

Almost 10 years since the U.S. Biosimilars Pathway the law which comprises of the Biologics Price Competition and Innovation was introduced. In the years 2015 the first of kind biosimilar product in U.S. history was introduced and launched in 2015. This consisted of long term court cases and later as the years passed Ten new biosimilars were approved and launched in 2019. 

The Food and Drug Administration (FDA) till now has given green light to new 26 biosimilars in total, including biosimilars of nine of the world’s most important biologic medicines: Avastin, Rituxan, Enbrel, Herceptin, Humira, Neupogen, Neulasta, Remicade and Epogen. This has been possible due to the relentless efforts of the biosimilar litigations attorney. 

The Supreme Court and Federal Circuit have given provisions of the enactment. 2019 did not offer any key insights into the enacment, but a number of trends emerged and lessons were learned. 

How biosimilar litigation attorneys help you with Patent litigations between biosimilar competitors of the same biologic medicine 

Biosimilar makers are filing for and obtaining manufacturing patent rights for their own as they do not have to use the manufacturing processes of the main manufacturers to obtain approval for their products. Then in 2019 we saw the first lawsuit between two biosimilar makers — both with biosimilars of AbbVie’s adalimumab (Humira). Then in January 2019, Coherus BioSciences, a biosimilar manufacturer, filed a complaint alleging that Amgen’s biosimilar of adalimumab (Amgevita) copied the patents for its own biosimilar version of adalimumab. From our resources we can say that Amgen launched Amgevita in Europe but officially it has manufactured Amgevita in the United States. Coherus claimed that production of Amgevita in the United States copied the main components of the patents. Now with the help of  biosimilar litigation attorneys the parties settled the suit in November 2019. 

According the experts Amgen holds the earliest launch date in the United States of any biosimilar adalimumab and definitely soon will launch in January 2023. Following that Coherus will launch in December 2023. 

We are going to see patent copying litigation between biosimilar competitors in the years coming ahead as biosimilar makers continue to procure and enforce patents. So will the need for biosimilar litigations attorneys. 

Expired patents may result in substantial damages imposed on the requester; the Safe Harbor does not save the companies from the pre-approved manufacturing. 

Amgen’s lawsuit with Pfizer’s Hospira involving a biosimilar of erythropoietin (EPO) has given us quite lot of illustration to very important lessons: patents that are expired at the time of biosimilar approval may still find some value to innovators at the end of the day, and the Safe Harbor provision of 35 U.S.C. 271(e)(1) does not prevent innovators from all preapproval manufacture taken care by the biosimilar legislation attorney. 

In December 2019, the Federal Circuit passed a new jury verdict that Amgen’s expired patent was copied and cannot be considered as originator drug. Then 14 batches of Hospira’s EPO biosimilar were not being protected by the Safe Harbor provision; and then the Amgen was entitled to $70 million in damages as a fine. The Federal Circuit then made it very clear that preapproval production of a biosimilar product is not necessarily protected by the Safe Harbor provision but they can be protected only if the biosimilar batches are made solely for regulatory purposes. 

In another case that involved Amgen’s complaint that was filed in September 2015 alleged that Hospira infringed some of its U.S. Patents and related methods of developing EPO. When the complaint was filed, Hospira’s biosimilar was not approved and launched in the United States. Hospira claimed that before the ban its 21 batches of biosimilar EPO, which were prepared during the time period of 2013 and 2015, before the expiration of the patents, are protected within the Safe Harbor provision because the products were related to the development and approval of information. 

During the trial, Amgen concluded that their 21 batches of Hospira’s EPO had the total estimated value of over $100 million. The jury found that the claims of the patent were surely infringed and not valid, and out which 14 of the 21 batches were not protected by the Safe Harbor provision. The jury awarded Amgen the case and was given $70 million in damages.  

Settlements abound and the USPTO intervenes in biosimilar IPR appeals post-settlement 

According to Biosimilar legislation attorney makers are taking advantage of the make use of inter partes review (IPR) proceedings to challenge against the verdict of the patents protecting biologic medicines and to finally get the approval for the drive settlements. When finally, the settlements occur after a final written verdict taken by the Patent Trial and Appeal Board (PTAB) which eventually leads to the biosimilar maker withdraws from the case, the U.S. Patent and Trademark Office (USPTO) is pulling up to protect the PTAB’s decision. 

Another example is of AbbVie that appealed the PTAB’s Final Decision finding claims of U.S. Patent directed to the methods of using adalimumab which was not protected by the trademark. Although Coherus BioSciences and Boehringer Ingelheim settled with AbbVie and withdrew from the appeal, the USPTO had to come into the case to protect the PTAB’s decision.  

In the same way, Biogen appealed against the PTAB’s Final Written Decision finding all claims of U.S. Patent No. 8,821,873. The case was related to the methods of treating diffuse large cell lymphoma with anti-CD20 antibodies. After the settlement between Pfizer and Biogen which was withdrawn from the court, eventually the United States government had to intervened in response to Biogen’s constitutional in order to challenge its pre-AIA patent to an IPR. Resulting in USPTO intervention to uphold the PTAB’s final verdict.

It would be interesting to see how biosimilar producers develop new scenarios for approval and launching the same in the market. But in the same way the experience required by biosimilar litigation attorneys is still very high. The biosimilar litigation attorneys would have to very minutely observe the present scenarios and the success failure rate connected to each case. 

That way the past case experiences have been handled would eventually play a major role in creating future success rates.

[anyx56]

PDF Science Lessons: What the Business of Biotech Taught Me About Management EBOOK BY Gordon Binder

Download Or Read PDF Science Lessons: What the Business of Biotech Taught Me About Management - Gordon Binder Free Full Pages Online With Audiobook.

  [*] Download PDF Visit Here => https://best.kindledeals.club/1591398614

[*] Read PDF Visit Here => https://best.kindledeals.club/1591398614

Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations

[nickwbenson]

Day 18

Another day in the books, but this was probably the toughest one yet. My fever last night kept rising, so at around 1am (after consulting with the on-call night nurse at the oncology ward) I made my way into the hospital. They don't know for sure that I have an infection, but given how immunocompromised I am they need to treat any fever as such.

At around 1:30am I was hooked up to an IV and they started pumping antibiotics into my bloodstream. I had four bags to get through, so I was teetering on the edge of sleep until about 4am when I finally finished up for the night. I got a decent five hours of fitful rest--gotta love hospital beds--and then woke up to a chest x-ray and more IVs in the morning.

All day I have been feeling nauseous, and I can't tell if it's from the Neupogen shots, the antibiotics, or anticipatory nausea as a result of my surprisingly traumatic hospital stay in Days 1-3. I think a good chunk of it has to be the association, because I have been able to eat very little all day. I had a croissant courtesy of the hospital for breakfast, and ordered Nando's in for lunch. I could barely eat any of it, and a granola bar is pretty much all that supported me through the afternoon. For dinner my mom dropped off homemade chicken noodle soup in a thermos, which was absolutely delicious, and yet that too was a struggle to consume.

It's incredibly difficult to be locked up in one room for 24 hours a day. I left the room once today (for my x-ray). I wasn't even allowed to walk down to radiation; hospital policy dictates that I be wheeled down in a chair by a member of staff. Apart from that, I have been either on the bed or in the one provided chair. Nobody is allowed to visit, and I am not allowed to leave until I am discharged. I couldn't even break out if I wanted to--the elevators require an ID card in order to operate.

I'm really starting to see why people say that fighting cancer is as much mental as it is physical. I also don't think that there's a rigid separation between the two--the mental bleeds into the physical and vice versa. I'm sure that's not a hot take by any means, but I'm feeling the overlap very viscerally right now.

I start Cycle 2 on Friday, and I was desperately hoping to be recharging at home right now. Instead I'm sitting in a hospital room with no set end date, feeling perfectly fine but unable to leave. I'm really hoping my fever dissipates ASAP so I can get home for at least a day or two before the next cycle commences.